Literature DB >> 16669852

Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999).

Aukje K Mantel-Teeuwisse1, Olaf H Klungel, Albert Hofman, W M Monique Verschuren, Paul H Trienekens, Arijan J Porsius, Bruno H Ch Stricker, Anthonius de Boer.   

Abstract

BACKGROUND: The success of the full implementation of a new guideline may depend on the observed discrepancy between daily medical practice developed before the release of the guideline and new treatment recommendations issued by the guideline. AIM: To assess whether the initiation of statin treatment for primary prevention of cardiovascular disease in an elderly population was in agreement with guidelines.
METHODS: Data were obtained from the Rotterdam Study, a prospective population-based cohort study consisting of 7983 subjects aged>or=55 years. In the period 1992-1999, all patients starting statins for primary prevention were selected. Treatment eligibility was established according to Dutch guidelines based on considerations of cost effectiveness (1998) and European guidelines based on clinical effectiveness (1998 and 2003).
RESULTS: Only 5.7% [95% confidence interval (CI) 3.1, 8.3] of the 299 subjects starting statins for primary prevention met the eligibility criteria of the Dutch guidelines. Most patients (92.0%, 95% CI 88.9, 95.1) met the criteria of the 2003 European guidelines. Patients who did not meet any eligibility criteria were female and had one or less cardiovascular risk factor, except for two patients with total cholesterol levels<5 mmol l-1 prior to start of statin therapy.
CONCLUSIONS: The use of statins was in agreement with the most recent European guidelines in over 90% of elderly patients who started statins for primary prevention, but in only 6% of these patients according to the Dutch guidelines. As long as existing guidelines are as discrepant as they are now, variation in agreement between physicians' prescribing and guideline recommendations is unavoidable.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16669852      PMCID: PMC1885064          DOI: 10.1111/j.1365-2125.2006.02634.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  [Higher prevalence of familial hypercholesterolemia than expected in adult patients of four family practices in Netherlands].

Authors:  P J Lansberg; S Tuzgöl; M A van de Ree; J C Defesche; J J Kastelein
Journal:  Ned Tijdschr Geneeskd       Date:  2000-07-22

2.  What do we gain from the sixth coronary heart disease drug?

Authors:  Rebecca N Warburton
Journal:  BMJ       Date:  2003-11-29

3.  Expanding statin use to help more at-risk patients is causing financial heartburn.

Authors:  Mike Mitka
Journal:  JAMA       Date:  2003-11-05       Impact factor: 56.272

4.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

5.  Undertreatment of hypercholesterolaemia: a population-based study.

Authors:  A K Mantel-Teeuwisse; W M M Verschuren; O H Klungel; D Kromhout; A D Lindemans; J Avorn; A J Porsius; A de Boer
Journal:  Br J Clin Pharmacol       Date:  2003-04       Impact factor: 4.335

6.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

Authors:  James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp
Journal:  Lancet       Date:  2002-11-23       Impact factor: 79.321

7.  Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated?

Authors:  Aukje K Mantel-Teeuwisse; Olaf H Klungel; W M Monique Verschuren; Arijan J Porsius; Anthonius de Boer
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

8.  Repeated nitrate prescriptions as a potential marker for angina pectoris. A comparison with medical information from the Rotterdam Study.

Authors:  Anke Hilse Maitland-van der Zee; Olaf H Klungel; Bruno H Ch Stricker; Deirdre A M van der Kuip; Jacqueline C M Witteman; Albert Hofman; Hubertus G M Leufkens; Anthonius de Boer
Journal:  Pharm World Sci       Date:  2003-04

9.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

Authors:  Guy De Backer; Ettore Ambrosioni; Knut Borch-Johnsen; Carlos Brotons; Renata Cifkova; Jean Dallongeville; Shah Ebrahim; Ole Faergeman; Ian Graham; Giuseppe Mancia; Volkert Manger Cats; Kristina Orth-Gomér; Joep Perk; Kalevi Pyörälä; José L Rodicio; Susana Sans; Vedat Sansoy; Udo Sechtem; Sigmund Silber; Troels Thomsen; David Wood
Journal:  Eur Heart J       Date:  2003-09       Impact factor: 29.983

10.  Cardiovascular disease risk profiles.

Authors:  K M Anderson; P M Odell; P W Wilson; W B Kannel
Journal:  Am Heart J       Date:  1991-01       Impact factor: 4.749

View more
  3 in total

1.  Explanatory model of prescribing behavior in prescription of statins in family practice.

Authors:  Ksenija Tusek-Bunc; Janko Kersnik; Marija Petek-Ster; Davorina Petek; Zalika Klemenc-Ketis
Journal:  Wien Klin Wochenschr       Date:  2010-05       Impact factor: 1.704

2.  A prescription for better prescribing.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

3.  The effectiveness of national guidance in changing analgesic prescribing in primary care from 2002 to 2009: an observational database study.

Authors:  J Bedson; J Belcher; O I Martino; M Ndlovu; T Rathod; K Walters; K M Dunn; K P Jordan
Journal:  Eur J Pain       Date:  2012-07-02       Impact factor: 3.931

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.